Citations to this article


Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.


Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg


Total citations by year

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 19 55 32 33 29 26 31 16 1 242
Citation information

Citations to this article in year 2009 (31)

Title and authors Publication Year
Immune Therapy for Cancer
M Dougan, G Dranoff
Annual Review of Immunology 2009
IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors
R Rosell, J Bertran-Alamillo, MA Molina, M Taron
Future Oncology 2009
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
M Hedvat, D Huszar, A Herrmann, JM Gozgit, A Schroeder, A Sheehy, R Buettner, D Proia, CM Kowolik, H Xin, B Armstrong, G Bebernitz, S Weng, L Wang, M Ye, K McEachern, H Chen, D Morosini, K Bell, M Alimzhanov, S Ioannidis, P McCoon, ZA Cao, H Yu, R Jove, M Zinda
Cancer Cell 2009
A component of polysaccharide peptidoglycan complex onLactobacillusinduced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer
S Matsumoto, T Hara, M Nagaoka, A Mike, K Mitsuyama, T Sako, M Yamamoto, S Kado, T Takada
Immunology 2009
Janus Kinase Mutations
RL Levine
Seminars in Oncology 2009
STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria
L Samavati, R Rastogi, W Du, M Hüttemann, A Fite, L Franchi
Molecular Immunology 2009
STATs in cancer inflammation and immunity: a leading role for STAT3
H Yu, D Pardoll, R Jove
Nature Reviews Cancer 2009
The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells
A Sahni, MT Arévalo, SK Sahni, PJ Simpson-Haidaris
International Journal of Cancer 2009
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling
J Inokuchi, A Lau, DR Tyson, DK Ornstein
Carcinogenesis 2009
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
DJ Gough, A Corlett, K Schlessinger, J Wegrzyn, AC Larner, DE Levy
Science 2009
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression
YP Luo, H Zhou, J Krueger, C Kaplan, D Liao, D Markowitz, C Liu, T Chen, TH Chuang, R Xiang, RA Reisfeld
Oncogene 2009
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
M Walter, S Liang, S Ghosh, PJ Hornsby, R Li
Oncogene 2009
Serum levels of nicotinamide N-methyltransferase in patients with lung cancer
M Tomida, I Mikami, S Takeuchi, H Nishimura, H Akiyama
Journal of Cancer Research and Clinical Oncology 2009
Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells
K Komiya, N Sueoka-Aragane, A Sato, T Hisatomi, T Sakuragi, M Mitsuoka, T Sato, S Hayashi, H Izumi, M Tsuneoka, E Sueoka
Journal of Cancer Research and Clinical Oncology 2009
Activation of Stat3 in renal tumors
C Guo, G Yang, K Khun, X Kong, D Levy, P Lee, J Melamed
American journal of translational research 2009
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway
KS Nguyen, S Kobayashi, DB Costa
Clinical Lung Cancer 2009
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
S Veeriah, C Brennan, S Meng, B Singh, JA Fagin, DB Solit, PB Paty, D Rohle, I Vivanco, J Chmielecki, W Pao, M Ladanyi, WL Gerald, L Liau, TC Cloughesy, PS Mischel, C Sander, B Taylor, N Schultz, J Major, A Heguy, F Fang, IK Mellinghoff, TA Chan
Proceedings of the National Academy of Sciences 2009
The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells
BD Adams, DM Cowee, BA White
Molecular Endocrinology 2009
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells
H Xin, C Zhang, A Herrmann, Y Du, R Figlin, H Yu
Cancer research 2009
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
S Grivennikov, E Karin, J Terzic, D Mucida, GY Yu, S Vallabhapurapu, J Scheller, S Rose-John, H Cheroutre, L Eckmann, M Karin
Cancer Cell 2009
Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease
P Qu, J Roberts, Y Li, M Albrecht, OW Cummings, JN Eble, H Du, C Yan
Lung cancer (Amsterdam, Netherlands) 2009
Therapeutic targeting of myeloid-derived suppressor cells
S Ugel, F Delpozzo, G Desantis, F Papalini, F Simonato, N Sonda, S Zilio, V Bronte
Current Opinion in Pharmacology 2009
ErbB receptors and signaling pathways in cancer
NE Hynes, G MacDonald
Current Opinion in Cell Biology 2009
gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
J Bollrath, TJ Phesse, VA von Burstin, T Putoczki, M Bennecke, T Bateman, T Nebelsiek, T Lundgren-May, Ö Canli, S Schwitalla, V Matthews, RM Schmid, T Kirchner, MC Arkan, M Ernst, FR Greten
Cancer Cell 2009
Interleukin-6-producing undifferentiated thymic carcinoma with neuroendocrine features
M Suzuki, N Shinagawa, S Oizumi, K Fugo, M Nishimura
Lung Cancer 2009